Skip to content
Clinical Trials – home
SpainBack to Spain

Clinical trials in Centelles – page 163

3 673 clinical trials in Centelles, Spain across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
Centelles at a glance
3 673
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

3 673 trials in Centelles

Open in trial search

Evaluation of HLX10 Combined with Chemotherapy and Radiotherapy in Limited-Stage Small Cell Lung Cancer: A Phase III Randomized, Double-Blind Study

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Serplulimab
  • Sponsor:Shanghai Henlius Biotech Inc.

Efficacy of Cobolimab, Dostarlimab, and Docetaxel in Advanced Non-Small Cell Lung Cancer Post Anti-PD(L)1 Therapy and Chemotherapy

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Cobolimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Efficacy and Safety Evaluation of Odevixibat in Pediatric Biliary Atresia Post-Kasai Hepatoportoenterostomy: A Double-Blind, Randomized, Placebo-Controlled Trial

Investigational
Countries:SpainSpain
  • Participants:0–17 years
  • Substances:Odevixibat
  • Sponsor:Ipsen Pharma

Phase III Study Comparing FOLFOX Plus Panitumumab Followed by FOLFIRI Plus Bevacizumab Versus FOLFOX Plus Bevacizumab Followed by FOLFIRI Plus Panitumumab in Wild-Type RAS Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Asociacion Grupo Tratamiento De Tumores Digestivos

A study evaluating glofitamab and a drug combination for patients with relapsed or refractory diffuse large B-cell lymphoma.

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Glofitamab
  • Sponsor:F. Hoffmann-La Roche AG

Efficacy, Safety, and Immunogenicity of mRNA-1647 Vaccine in Preventing Primary Cytomegalovirus Infection in CMV-Seronegative Females Aged 16-40

Registered drug
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · Healthy volunteers
  • Substances:Sodium Chloride
  • Sponsor:Moderna Inc.

A Phase 3 Randomized Open-Label Study of Sacituzumab Govitecan Versus Physician's Choice in Recurrent or Persistent Endometrial Cancer Post-Chemotherapy and Immunotherapy

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Paclitaxel
  • Sponsor:Gilead Sciences Inc.

Evaluation of Pembrolizumab, Patritumab Deruxtecan, and Drug Combinations in Stage IV Non-Small Cell Lung Cancer: A Phase 2 Umbrella Study

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Plasma cell myeloma

Not recruiting

Efficacy and Safety Evaluation of Belantamab Mafodotin Versus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Belantamab Mafodotin
  • Sponsor:Glaxosmithkline Research & Development Limited

Neoplasm malignant

Not recruiting

Phase 1 Study of ADCT-901 in Patients with Advanced Solid Tumors to Evaluate Safety, Tolerability, Pharmacokinetics and Antitumor Activity

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:ADCT-901
  • Sponsor:ADC Therapeutics SA

Phase 1/2 Evaluation of Zilovertamab Vedotin in PD-1/L1 Refractory Locally Advanced or Metastatic Urothelial Carcinoma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Phase 3 Study of Subcutaneous Pembrolizumab with Hyaluronidase vs. Intravenous Pembrolizumab in Metastatic NSCLC with PD-L1 TPS ≥50%

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Other cities in Spain

The busiest research cities in the country

All 210 cities in Spain

Clinical research in Centelles

What the registry says about research in the country

01 Infectious Disease Prevention

Comprehensive research focusing on viral infections including studies evaluating vaccines against SARS-CoV-2, Herpes Zoster, and Cytomegalovirus. Multiple trials are examining vaccine efficacy and immune response in different age groups.

  • COVID-19 Vaccine Development
  • Viral Disease Prevention
  • Vaccine Safety Studies

Special attention is given to vaccine co-administration studies and booster dose evaluations in various populations.

02 Respiratory Health

Innovative clinical research examining treatments for respiratory conditions, including studies on RSV vaccines for older adults and asthma medication delivery systems. These trials aim to enhance treatment options for respiratory diseases.

  • RSV Prevention
  • Asthma Management
  • Pneumococcal Disease

Focus on developing effective preventive measures and treatments for respiratory infections.

03 Cardiovascular Health

Advanced research into cardiovascular disease prevention and treatment, with emphasis on managing hypercholesterolemia and reducing major adverse cardiovascular events. Studies evaluate new therapeutic approaches for heart health.

  • Cholesterol Management
  • Cardiovascular Risk Reduction
  • Preventive Cardiology

Trials focus on innovative medications and preventive strategies for cardiovascular health improvement.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.